Status:
COMPLETED
Anti-Argonaute Antibodies for the Diagnosis of Sensory Neuronopathies
Lead Sponsor:
Centre Hospitalier Universitaire de Saint Etienne
Conditions:
Autoimmune Diseases
Eligibility:
All Genders
18+ years
Brief Summary
Argonaute (AGO) proteins have been described as the target of antibodies in several autoimmune diseases including Sjögren Syndrome (SS). Sensory neuronopathies (SNN) are disorders affecting neurons in...
Detailed Description
Sensory neuronopathies (SNN) are rare and debilitating diseases that fall under several etiologies. Among them, dysimmune forms are the most frequent but very difficult to identify when they do not oc...
Eligibility Criteria
Inclusion
- Patients with sensory neuropathy
Exclusion
- Patient not tested for anti-AGO antibody
Key Trial Info
Start Date :
May 27 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 27 2023
Estimated Enrollment :
630 Patients enrolled
Trial Details
Trial ID
NCT05966350
Start Date
May 27 2021
End Date
January 27 2023
Last Update
July 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Saint-Etienne
Saint-Etienne, France, 42055